ストックスクリーナーアプリを入手
6.75
8.00%
0.50
アフターアワーズ：
6.60
-0.15
-2.22%
前日終値:
$6.25
開ける：
$6.29
24時間の取引高:
1.70M
Relative Volume:
1.08
時価総額：
$691.42M
収益：
-
当期純損益:
$-167.48M
株価収益率:
-3.4615
EPS:
-1.95
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
+10.66%
1か月 パフォーマンス:
+2.74%
6か月 パフォーマンス:
-44.94%
1年 パフォーマンス:
-52.57%
1日の値動き範囲:
$6.2548
$6.77
1週間の範囲:
$5.90
$6.77
52週間の値動き範囲:
$5.635
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.75 | 640.20M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Day One Biopharmaceuticals Receives Bullish Ratings from Analysts Amid Promising Growth Prospects - AInvest
Published on: 2025-08-11 05:16:25 - beatles.ru
Is Day One Biopharmaceuticals Inc. Forming a Consolidation BaseLow Risk Equity Screener With Results Shared - beatles.ru
Day One Biopharmaceutical Stock Price, Quotes and Forecasts | NASDAQ:DAWN - Benzinga
Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
Day One Biopharmaceuticals Maintains Buy Rating on Promising Growth and Strategic Innovation - AInvest
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $16 to $26 - 富途牛牛
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks
Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals - TipRanks
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge - AInvest
Day One Biopharmaceuticals shares fall 14.24% premarket after Q2 2025 earnings call. - AInvest
Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate - MSN
Day One Biopharmaceuticals (DAWN): A High-Growth Biotech Play in Pediatric Oncology with a Clear Path to Value Creation - AInvest
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Biopharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Day One Biopharma Reports Strong Q2 2025 Growth - TipRanks
Day One Biopharmaceuticals Reports Q2 2025 Financial Results and Strategic Appointments. - AInvest
Day One Biopharmaceuticals' Q2 2025: Unpacking Contradictions in Treatment Durability, Financial Projections, and Growth Trajectory - AInvest
Day One Biopharmaceuticals: Scaling OJEMDA Revenue While Strengthening R&D and Financial Discipline - AInvest
Transcript : Day One Biopharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Day One Biopharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Day One Biopharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c) - TipRanks
Day One Biopharmaceuticals Q2 Revenue Rises Amid Leadership Changes and Earnings Calls - AInvest
Day One Biopharmaceuticals Q2 OJEMDA revenue rises - MarketScreener
Day One Biopharmaceuticals Reports Q2 2025 Financial Results, Expects $140-150M in OJEMDA Net Product Revenue for FY25 - AInvest
What are analysts’ price targets for Day One Biopharmaceuticals Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
How volatile is Day One Biopharmaceuticals Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
What is the risk reward ratio of investing in Day One Biopharmaceuticals Inc. stock - Jammu Links News
Is it the right time to buy Day One Biopharmaceuticals Inc. stockCapitalize on high-yield stock opportunities - Jammu Links News
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastCapitalize on emerging trends for profits - Jammu Links News
Why is Day One Biopharmaceuticals Inc. stock attracting strong analyst attentionFree Investment Community - Jammu Links News
How does Day One Biopharmaceuticals Inc. generate profit in a changing economyTremendous growth opportunities - Jammu Links News
Is Day One Biopharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
How many analysts rate Day One Biopharmaceuticals Inc. as a “Buy”Unbelievable profit margins - Jammu Links News
What are the technical indicators suggesting about Day One Biopharmaceuticals Inc.Build a portfolio that outperforms consistently - Jammu Links News
Does Day One Biopharmaceuticals Inc. stock perform well during market downturnsPhenomenal trading returns - Jammu Links News
How strong is Day One Biopharmaceuticals Inc. company’s balance sheetInvest smarter with cutting-edge analytics - Jammu Links News
What makes Day One Biopharmaceuticals Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
Day One Biopharmaceuticals Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Can a trend reversal in Day One Biopharmaceuticals Inc. lead to recoveryYield Curve Outlook and Long-Term Implication Summary - Newser
Day One Biopharmaceuticals Inc. stock chart pattern explainedRisk/Reward Optimization Entry Point Analysis - Newser
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - 富途牛牛
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):